Cardiac Safety Monitor
Monopar Therapeutics, Inc., Switzerland
Pierre Jordaan practiced as an invasive cardiologist at the University Hospital, University of the Free State with emphasis on pacemakers and arrhythmias before moving into early phase research. He acted as Principal Investigator of more than 150 studies in fields covering cardiology, ophthalmology, orthopedics, rhumatology and HIV. Relocating to Switzerland he was Translational Expert in Cardiovascular Research, and transitioned a novel treatment for heart failure from the preclinic to the clinic and eventally to registration.
Building on a this he was appointed as a standing member of the Medical Safety Review Board at Novartis, with responsibility of overseeing cardiovascular safety secially in oncology trials for almost 10 years, establishing standardised company-wide monitoring strategies for cardiotoxicity. Recently he terminated full-time employment to act as consultant for cardiovascular safety, and serve as honorary CMO for Mudiro, as Swiss voluntary organisation in the remote northeast of Namibia.